FRNM — Freenome, Inc.
Is FRNM overbought or oversold? Here is the current MarketMoodz read.
Freenome, Inc. (FRNM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $9.82. The rating moved from Strong Oversold to Oversold on November 10, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$9.82
- Last changeMoved from Strong Oversold to Oversold on November 10, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Freenome, Inc. (FRNM) is an early commercial-stage diagnostics company focused on multiomics liquid biopsy for cancer detection. Financially, the company faces typical early-stage diagnostics dynamics: likely negative operating cash flow, dependence on capital markets or partnerships for runway, and sensitivity to dilution. Competitive strengths include a differentiated platform and ongoing clinical programs; however, commercialization scale requires payer coverage, clinician uptake, and clear clinical utility readouts. Near-term catalysts include clinical/validation data releases and partnership or reimbursement wins; downside scenarios center on clinical setbacks, unfavorable coverage decisions, or substantial dilution. Social sentiment and research coverage are limited, so share moves will be headline-driven. Over the coming weeks to months, progress on clinical milestones and any payer announcements will be the key determinants of directional performance.
Key factors
- Proprietary multiomics liquid biopsy platform with potential in early cancer detection and screening
- Clinical validation progress and any upcoming assay/clinical readouts are the primary near‑term catalysts
- Commercialization traction is limited so far; success depends on provider adoption and payer coverage
- Competitive landscape includes well‑funded players (e.g., liquid biopsy incumbents and diagnostics firms) that can pressure pricing and market share
- Macroeconomic/market tone currently shows selective support for growth names, which could modestly help share price if diagnostic news is positive
- Regulatory and reimbursement environment (Medicare/payer decisions) will materially affect revenue visibility and timing
Risks
- Clinical or validation setbacks that reduce confidence in assay performance or broad screening utility
- Failure to secure favorable reimbursement or coverage policies from Medicare and commercial payers, slowing adoption
- Intense competition from larger diagnostics and biotech companies with greater distribution and marketing resources
- High cash burn and need for additional capital that could lead to dilution or governance pressure
- Regulatory changes or increased program integrity scrutiny that affect diagnostic billing and reimbursement dynamics
- Limited public sentiment and sparse social/research coverage, increasing volatility on headline-driven moves
See today's live rating, score and targets
Members see the live hourly rating for FRNM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.